BIOGEN INC (BIIB) Stock Fundamental Analysis
USA - NASDAQ:BIIB - US09062X1037 - Common Stock
164.73 USD
+3.25 (+2.01%)
165.68 USD
+0.95 (+0.58%)
Overall BIIB gets a fundamental rating of 6 out of 10. We evaluated BIIB against 531 industry peers in the Biotechnology industry. BIIB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. BIIB is cheap, but on the other hand it scores bad on growth. These ratings would make BIIB suitable for value investing!
1. Profitability
1.1 Basic Checks
BIIB had positive earnings in the past year.
BIIB had a positive operating cash flow in the past year.
Each year in the past 5 years BIIB has been profitable.
BIIB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BIIB's Return On Assets of 5.51% is amongst the best of the industry. BIIB outperforms 91.71% of its industry peers.
Looking at the Return On Equity, with a value of 8.83%, BIIB belongs to the top of the industry, outperforming 92.66% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 9.70%, BIIB belongs to the top of the industry, outperforming 94.54% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BIIB is significantly below the industry average of 15.76%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.83% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
With an excellent Profit Margin value of 15.98%, BIIB belongs to the best of the industry, outperforming 93.22% of the companies in the same industry.
In the last couple of years the Profit Margin of BIIB has declined.
With an excellent Operating Margin value of 28.50%, BIIB belongs to the best of the industry, outperforming 96.42% of the companies in the same industry.
In the last couple of years the Operating Margin of BIIB has declined.
BIIB has a better Gross Margin (75.24%) than 83.80% of its industry peers.
BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BIIB is still creating some value.
Compared to 1 year ago, BIIB has more shares outstanding
Compared to 5 years ago, BIIB has less shares outstanding
BIIB has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.21 indicates that BIIB is not in any danger for bankruptcy at the moment.
The Altman-Z score of BIIB (3.21) is better than 71.00% of its industry peers.
The Debt to FCF ratio of BIIB is 2.78, which is a good value as it means it would take BIIB, 2.78 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.78, BIIB belongs to the best of the industry, outperforming 93.22% of the companies in the same industry.
A Debt/Equity ratio of 0.35 indicates that BIIB is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.35, BIIB is not doing good in the industry: 70.43% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.21 |
ROIC/WACC1.19
WACC8.15%
2.3 Liquidity
A Current Ratio of 2.72 indicates that BIIB has no problem at all paying its short term obligations.
With a Current ratio value of 2.72, BIIB is not doing good in the industry: 66.85% of the companies in the same industry are doing better.
BIIB has a Quick Ratio of 2.04. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.04, BIIB is doing worse than 72.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
BIIB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.51%.
The earnings per share for BIIB have been decreasing by -13.31% on average. This is quite bad
BIIB shows a small growth in Revenue. In the last year, the Revenue has grown by 4.77%.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
BIIB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.52% yearly.
The Revenue is expected to decrease by -0.65% on average over the next years.
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
BIIB is valuated reasonably with a Price/Earnings ratio of 9.84.
Based on the Price/Earnings ratio, BIIB is valued cheaply inside the industry as 97.55% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 25.91, BIIB is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 10.55, the valuation of BIIB can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.36% of the companies listed in the same industry.
BIIB is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.57, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.84 | ||
| Fwd PE | 10.55 |
4.2 Price Multiples
98.12% of the companies in the same industry are more expensive than BIIB, based on the Enterprise Value to EBITDA ratio.
BIIB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.68 | ||
| EV/EBITDA | 7.26 |
4.3 Compensation for Growth
The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
5. Dividend
5.1 Amount
BIIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
164.73
+3.25 (+2.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner Change0.63%
Ins Owners0.14%
Ins Owner Change3.17%
Market Cap24.15B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.81
Price Target175.03 (6.25%)
Short Float %3.55%
Short Ratio3.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)1.06%
PT rev (3m)1.25%
EPS NQ rev (1m)-54.54%
EPS NQ rev (3m)-55.25%
EPS NY rev (1m)-4.15%
EPS NY rev (3m)1.63%
Revenue NQ rev (1m)-2.22%
Revenue NQ rev (3m)-2.13%
Revenue NY rev (1m)0.95%
Revenue NY rev (3m)5.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.84 | ||
| Fwd PE | 10.55 | ||
| P/S | 2.4 | ||
| P/FCF | 10.68 | ||
| P/OCF | 9.84 | ||
| P/B | 1.33 | ||
| P/tB | 10.13 | ||
| EV/EBITDA | 7.26 |
EPS(TTM)16.74
EY10.16%
EPS(NY)15.61
Fwd EY9.48%
FCF(TTM)15.43
FCFY9.37%
OCF(TTM)16.74
OCFY10.16%
SpS68.66
BVpS124.19
TBVpS16.27
PEG (NY)N/A
PEG (5Y)N/A
Graham Number216.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.83% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.45% | ||
| ROICexgc | 40.97% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.47% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.08% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.54% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.21 |
F-Score5
WACC8.15%
ROIC/WACC1.19
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
EBIT growth 1Y15.19%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y1.64%
FCF growth 1Y120.46%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.45%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / BIIB FAQ
Can you provide the ChartMill fundamental rating for BIOGEN INC?
ChartMill assigns a fundamental rating of 6 / 10 to BIIB.
What is the valuation status for BIIB stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.
How profitable is BIOGEN INC (BIIB) stock?
BIOGEN INC (BIIB) has a profitability rating of 7 / 10.
Can you provide the expected EPS growth for BIIB stock?
The Earnings per Share (EPS) of BIOGEN INC (BIIB) is expected to decline by -5.79% in the next year.